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Immunity to Human Rhinoviruses
Rhinovirus (RV) infections impose a major disease burden as they cause around three out of
four common colds and are responsible for the majority of acute exacerbations of chronic
obstructive pulmonary disease (COPD) and asthma [1, 2]. RVs therefore are associated with
an enormous economic cost in missed work or school and medical attention. Prophylactic
vaccination against infection is arguably the most effective medical intervention ever
developed, and has proven enormously effective in protecting against a large number of
diseases. However, at the present time no effective vaccine exists for RVs. This is largely due
to the existence of 100 serotyped antigenically distinct RV strains - such variability means that
a vaccine designed to elicit immune responses against a particular RV is unlikely to be able
to provide protection against the full range of virus subtypes successfully [3]. In fact, this
phenomenon was observed as early as 1965 when immunising with formalin inactivated whole
RV and is confirmed by the knowledge that the immunity induced following RV infection does
not significantly protect from future infection by different RV serotypes [4]. More sophisticated
attempts at immunisation with multiple inactivated RV serotypes also failed to induce
significant cross-serotype protection [5]. Thus, an effective cross-serotype responsive RV
vaccine has remained elusive. The relatively recent description of a new clade of RV types
(RV-C) has increased the number of identified strains/serotypes to ~160 [6]. Perhaps the quest
for a RV vaccine has been dismissed as too difficult or even impossible, but new developments
suggest that it may be feasible to generate a significant breadth of immune protection.
Subunit Vaccines and Adjuvants
The most effective existing viral vaccines are “live” formulations in which the patient is exposed
to an attenuated form of the virus. These replicate in the body mimicking the natural infection
without the induction of serious disease and thus lead to prolonged exposure to antigens,
inducing protective immunity. However, live vaccines are unlikely to deliver broadly reactive
immunity to RVs, for many of the same reasons that inactivated vaccines failed.
Thus, the application of subunit vaccines, which have been developed for other significant
human viral pathogens, such as hepatitis B virus and human papilloma virus [7], has now been
explored for RVs. In subunit vaccines, the immunogen comprises a small subunit or a virus-
like particle (VLP) form of the pathogen. By their very nature these do not cause infection.
However, most such non-infectious peptide-based vaccines are poorly immunogenic and rely
on the presence of an adjuvant to inculcate robust immunity by mimicking the danger signals
that naturally trigger immune responses. The addition of adjuvants to vaccines enhances the
immunogenicity of antigens, and reduces the number of immunizations required.
At present, inorganic compounds known as ‘alums’ (usually either AlOOH or amorphous
aluminium hydroxyphosphate) are used as adjuvants in the vast majority of cases [8]. Alum
can promote strong antibody responses that are effective in inducing immunity to bacteria and
parasites (a Th2 response). However, it does not provoke strong Th1 immunity, which is
intrinsically linked to the cellular immune responses that are most potent against intracellular
pathogens. With respect to RVs, a Th1-biased immune response is likely to be desirable
because human memory T cell responses to RV have been demonstrated to be primarily Th1
orientated [9] and memory Th1 responses were found to be protective against virus shedding
after experimental infection [10]. RV infections are also known to enhance the Th2 responses
already found in asthma [11, 12]. A reconfiguration of this undesirable immune response to
Th1 could alleviate RV triggered exacerbations of allergic airway diseases.
Only alum, the oil-in-water emulsion adjuvants AS03 and MF59, and a new adjuvant
containing alum and monophosphoryl lipid A (AS04) are currently licensed for use in human
vaccines. These often do not provoke the correct pattern of immune response needed to most
effectively target a viral disease, although mixed Th1/Th2 responses can be promoted by
AS03 and MF59 [13]. In addition, despite the fact that it has been used for around 80 years in
the clinic, the mechanisms of action of alum are not well understood. Not for nothing is it known
as the immunologist’s “dirty little secret” [14].
Thus in addition to the immunogen, the adjuvant represents a key challenge to developing a
subunit RV vaccine.
Novel Adjuvants and Immune Response Tailoring
AlOOH is an inorganic material, but until very recently few attempts had been made to employ
materials chemistry approaches to develop new adjuvants. However, some important steps
forward have been taken to this end in the last 5 years. The effect of varying the particle size
and shape of alum has been explored, and nanoparticles found to be more potent as adjuvants
than particles on the micron scale [15]. In other work, rod shaped particles have been found
to promote stronger immune responses than plates or polyhedra [8]. A range of other inorganic
particles such as zinc and cobalt oxides, silver and gold nanoparticles have also been
discovered to possess adjuvanticity [8]. In the latter case, rod shaped particles were again
found to be more potent than other shapes.
Perhaps the most exciting finding is the recent discovery that layered double hydroxides
(LDHs), inorganic materials with compositions similar to alum, can act as potent adjuvants
[16]. LDHs contain metal hydroxide sheets which bear a positive charge, and charge-
balancing anions between these layers. They have the general formula [Mz+1-
qM3+q(OH)2]q+(Xn-)q/n·yH2O, and typically contain mixtures of mono-/di- and trivalent cations with
the interlayer anions comprising halides, nitrate, etc. A wide variety of metal ions and anions
can be incorporated into the LDH structure (e.g. [LiAl2(OH)6](CO3)0.5·yH2O;
[Mg2Al(OH)6]Cl·yH2O; [Ca2Al(OH)6]NO3·yH2O).
Different LDHs have been found to promote different responses across a range of cytokines
(e.g. IL-1β, IL-6, IL-12p70), chemokines (e.g. IL-8), costimulatory molecules (CD40, CD86) 
and antibodies (e.g. IgG1, IgG2c) [16]. The latter is particularly important: some LDHs
stimulate IgG1 (a Th2-associated antibody) at levels similar to or greater than alum while
others stimulate both IgG1 and IgG2c (a Th1-associated antibody) [16]. Thus, LDHs can drive
both Th2 and Th1 responses. Moreover, it proved possible to use mathematical modelling to
develop an equation linking the immune response provoked in vitro and in vivo to certain
physicochemical properties of the LDHs, permitting the response induced by an as-yet
untested adjuvant to be predicted a priori [16].
Other work has further shown that the [Mg2Al(OH)6]Cl·yH2O LDH conjugated with CpG can
also drive a strong Th1 response [17]. The discovery of such advanced adjuvants offers great
potential to incrementally tune the immune response, and might ultimately yield materials able
to produce a particular spectrum of immune response (cytokines, chemokines, co-stimulatory
molecules) at a greater level of specificity than a simple Th1/Th2 polarisation.
Recent Developments in Subunit Rhinovirus Vaccines
In recent work, areas of the RV capsid proteins VP4 and VP2 (VP0) and the 3’ region of the
viral polymerase were identified as being broadly conserved across RV serotypes [18]. These
regions have been assessed as potential subunit immunogens to induce broadly reactive
immunity to RV [18]. Using small animal models, immunization with RV-A16 VP0 protein in
combination with the Th1-directing incomplete Freund’s adjuvant and CpG promoted potent
Th1 immune responses, resulting in VP0-specific T cell IFN-γ production and induction of 
antibodies which bound multiple virus serotypes [18]. Robust cross-serotype (both to the
closely related serotype RV-A1 and importantly also distantly related serotypes RV-B14 and
RV-A29) RV-specific Th1 responses were seen systemically after VP0 immunisation, and also
in the lungs with VP0 immunisation followed by live intranasal heterologous RV challenge.
Furthermore, immunisation and RV challenge enhanced RV-neutralising antibody titres and
was associated with reduced viral load in vivo [18]. In other studies, immunisation of rabbits
with the RV VP1 capsid proteins of RV-B14 or RV-A89 generated antisera containing cross-
serotype RV-neutralising antibodies that weakly neutralised several distantly related RV
serotypes, suggesting that known regions of higher sequence similarity can induce cross-
neutralising antibodies even though neutralising antibodies tend to recognise native virion
structural epitopes [19]. Additionally, repeated immunisation of mice with inactivated RV-A1
preparations followed by live RV-A1 infection induced antibodies that predominantly bound
VP1 of multiple serotypes, and induced weak (up to a 1:32 dilution) neutralising activity against
RV-A16, further implicating VP1 as a potential vaccine candidate [20]. Thus, conserved protein
antigens exist within RVs and these can induce cross-reactive cellular and humoral immune
responses with protective abilities. These regions of RVs (VP0 or VP1) are applicable as
candidate subunit vaccines for RVs and warrant further investigation.
Future Outlook
The twin discoveries of tuneable adjuvants and potential immunogens which can provide
cross-serotype immunity to RV offer potential for future developments of a vaccine formulation
against this widespread disease. The combination of an adjuvant able to drive a highly Th1
polarised response and an immunogen which could lead to broad spectrum protection could
lead to robust protective immunity and minimal side effects in terms of undesirable airway
inflammation in individuals suffering from RV-induced exacerbations of asthma - the most
critical unmet medical need relevant to RVs.
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